Publications by authors named "Nam Yeong Park"
Article Synopsis
- Polo-like kinase 1 (PLK1) is a key player in regulating the cell cycle and is a promising target for cancer treatment.
- A new compound, DD-2, has been developed using the N-degron pathway to selectively degrade PLK1 in cancer cells, showing strong anticancer effects in lab tests.
- In studies with mouse models, DD-2 not only inhibited tumor growth but also worked well in combination with the tyrosine kinase inhibitor osimertinib, suggesting it may enhance current cancer therapies.
Cancer has been identified as a leading cause of death worldwide, and the increasing number of cancer cases threatens to shorten the average life expectancy of people. Recently, we reported a 3-azido-3-deoxythymidine (AZT)-based amphipathic small molecule, ADG-2e that revealed a notable potency against tumor metastasis. To evaluate the anticancer potential of ADG-2e, we assessed its anticancer potency in vitro and in vivo.
View Article and Find Full Text PDF